{"entity":{"id":"cervical","kind":"cancer","name":"Cervical cancer","aka":["CESC","TCGA-CESC","cervical squamous cell carcinoma and endocervical adenocarcinoma (TCGA CESC cohort)"],"tldr":"A cancer that could be eliminated by HPV vaccination and screening. For those who develop it, immunotherapy and a tissue-factor ADC have improved survival.","summary":"Cervical cancer is almost entirely caused by persistent infection with high-risk human papillomavirus, which makes it the one common cancer that could be eliminated: HPV vaccination prevents about 90% of cases, HPV screening finds the precancers that remain, and a minute of thermal ablation or a loop excision cures them. Around 660,000 women are diagnosed and 350,000 die each year, nine in ten of them in low- and middle-income countries where vaccination and screening have not reached. In Sweden, Scotland, and Australia, cohorts vaccinated at 12-13 show near-zero invasive cancer, and Australia expects to pass the WHO elimination threshold (4 per 100,000) around 2035.\n\nFor women who develop cancer, treatment depends on stage. Early disease is treated with open radical hysterectomy (minimally invasive surgery proved worse in the LACC trial) or, for the smallest tumours, fertility-sparing surgery, with sentinel node mapping under evaluation. Locally advanced disease is cured in roughly two-thirds by cisplatin chemoradiation with brachytherapy, and two 2023-24 trials improved on that standard for the first time since 1999: six weeks of induction carboplatin-paclitaxel (INTERLACE, 5-year OS 80% vs 72%) and pembrolizumab with chemoradiation (KEYNOTE-A18, 36-month OS 82.6% vs 74.8%). Metastatic or recurrent disease, once treated with chemotherapy alone, now has first-line chemotherapy plus a checkpoint inhibitor with or without bevacizumab (KEYNOTE-826, BEATcc, COMPASSION-16 in China), the tissue-factor ADC tisotumab vedotin in second line (innovaTV 301), and HER2-directed therapy for the minority with HER2-positive tumours.\n\nWhat comes next is mostly delivery rather than discovery: single-dose HPV vaccination and self-sampled HPV testing to reach the 90-70-90 targets, screen-and-treat with portable ablation devices, AI-read colposcopy, and cheaper immunotherapy access. On the treatment side, HPV ctDNA to guide who needs maintenance therapy, TROP2 ADCs (sacituzumab tirumotecan), TIL therapy, and therapeutic HPV vaccines are in trials. The enduring problem is that the tools already exist and the women who die do not have them.","asOf":"2026-09-07","wikipedia":"https://en.wikipedia.org/wiki/Cervical_cancer","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Cervical_cancer"}],"tags":["gyn","spike"],"related":["induction-chemo-then-crt","io-plus-crt-cervical","caution-mis-radical-hysterectomy","radiation-plus-io","early-detection-roadmap","vaginal"],"cancers":[],"sections":[],"technologies":["hpv-vaccine","brachytherapy","adc","checkpoint-inhibitor","til-therapy","probiotics-treatment-diarrhoea","hpv-testing","colposcopy-excision","precancer-ablation","imrt-igrt","sentinel-node","robotic-surgery","liquid-biopsy"],"targets":["tissue-factor","pd1","trop2","vegf","ctla4","her2","pdl1"],"drugs":[],"companies":["color-health","mabwell-shanghai-bioscience","bio-thera-solutions","neonc-technologies","merck","roche-genentech","genmab","pfizer","akeso","regeneron","nrg-oncology"],"institutions":["tikur-anbessa-hospital","iarc","cruk","md-anderson"],"pathways":[],"terms":["cin-hsil","cps","tumour-agnostic"],"trials":["mumbai-via-screening","nct07418749","nct05027776","nct07216703","nct04422366","nct07168200","nct06459180","nct06123884","nct05235516","nct06079671","nct06692166","nct04906993"],"people":["jade-goody"],"bottlenecks":[],"keyPapers":[],"journals":["international-journal-of-gynecological-cancer","journal-of-gynecologic-oncology"],"dependsOn":[],"notes":[],"group":"gynaecologic","burden":"Cervical cancer is almost entirely preventable by HPV vaccination and screening, and cohorts vaccinated at 12-13 show near-zero invasive cancer. It still causes ~660,000 cases and ~350,000 deaths per year, nine in ten in low- and middle-income countries; it is the fourth most common cancer in women worldwide and the leading cause of cancer death among women in many sub-Saharan African countries.","subtypes":["Squamous cell carcinoma (~75%; HPV16 predominant)","Adenocarcinoma (~20-25%; HPV18 enriched; rising share in screened populations)","Adenosquamous carcinoma","HPV-independent adenocarcinoma (gastric-type; ~5% of adenocarcinomas; behaves more aggressively)","Neuroendocrine carcinoma (rare; SCLC-like)","Precursor lesions: CIN2-3/HSIL, adenocarcinoma in situ"],"biomarkers":["HPV type","PD-L1 CPS","Tissue factor (not required)","High-risk HPV type (16, 18, others) and HPV status (HPV-independent tumours behave worse)","PD-L1 CPS (≥1 for pembrolizumab in recurrent disease; not required for KEYNOTE-A18)","p16 IHC (HPV surrogate)","HER2 (IHC 3+ for T-DXd; ~5-10%)","Tissue factor (not required for tisotumab)","Plasma HPV ctDNA (investigational monitoring)","FIGO 2018 stage incorporating imaging and nodal status","MSI/TMB (rare tumour-agnostic eligibility)"],"standardOfCare":[{"setting":"Prevention","approach":"HPV vaccination age 9-14; HPV primary screening.","refs":["hpv-vaccine"],"guideline":{"version":"NCCN Guidelines: Cervical Cancer","url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1426"}},{"setting":"Locally advanced","approach":"Cisplatin chemoradiation + brachytherapy + pembrolizumab.","refs":["brachytherapy","imrt-igrt","pembrolizumab"],"guideline":{"version":"NCCN Guidelines: Cervical Cancer","url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1426"}},{"setting":"Recurrent/metastatic","approach":"Pembrolizumab-chemotherapy-bevacizumab; tisotumab vedotin.","refs":["pembrolizumab","tisotumab-vedotin"],"guideline":{"esmoMcbs":"2 (innovaTV 204 tisotumab vedotin, single-arm)","version":"NCCN Guidelines: Cervical Cancer","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11163648/"}},{"setting":"Primary prevention","approach":"HPV vaccination of girls (and boys) at 9-14, one or two doses per WHO; catch-up to 26 (US label to 45). Reduces invasive cancer ~90% when given before exposure.","refs":["hpv-vaccine","gardasil-9","ken-she"],"guideline":{"nccn":"Prevention guideline","url":"https://www.who.int/publications/i/item/9789240014107"}},{"setting":"Screening","approach":"HPV primary testing every 5 years from 25-30 (self-sampling accepted), or cytology every 3 years; VIA or HPV screen-and-treat in low-resource settings; WHO target 70% screened twice in a lifetime.","refs":["hpv-testing","precancer-ablation","colposcopy-excision"],"guideline":{"nccn":"USPSTF Grade A"}},{"setting":"Precancer (HSIL / CIN2-3, AIS)","approach":"Colposcopy-directed biopsy then LEEP/LLETZ or cone excision; thermal ablation or cryotherapy where eligible; HPV test of cure at 6-12 months.","refs":["colposcopy-excision","precancer-ablation","cin-hsil"],"guideline":{"nccn":"ASCCP 2019 risk-based management"}},{"setting":"Stage IA1-IB1 (≤2 cm)","approach":"Simple hysterectomy is non-inferior to radical for low-risk IA2-IB1 ≤2 cm (SHAPE trial, 2024); cone or trachelectomy for fertility preservation; sentinel node mapping in trials (SENTICOL III).","refs":["robotic-surgery","sentinel-node","senticol-iii"],"guideline":{"nccn":"2A"}},{"setting":"Stage IB2-IIA (surgical candidates)","approach":"Open radical hysterectomy with pelvic lymphadenectomy (minimally invasive approach inferior in LACC); adjuvant radiation or chemoradiation for intermediate/high-risk pathology (Sedlis, Peters criteria).","refs":["lacc","caution-mis-radical-hysterectomy","imrt-igrt","cisplatin"],"guideline":{"nccn":"1 (open approach)"}},{"setting":"Locally advanced (IB3, IIB-IVA), standard","approach":"Weekly cisplatin 40 mg/m² with external-beam IMRT/IGRT followed by image-guided brachytherapy to ≥85 Gy EQD2, completed within 56 days.","refs":["cisplatin","imrt-igrt","brachytherapy"],"guideline":{"nccn":"1","esmoMcbs":"A"}},{"setting":"Locally advanced, high risk (node-positive IB2-IIB, III-IVA)","approach":"Add pembrolizumab during chemoradiation and for 15 maintenance cycles (KEYNOTE-A18, approved 2024 for FIGO III-IVA), or induction carboplatin-paclitaxel weekly × 6 before chemoradiation (INTERLACE). Adjuvant chemotherapy after chemoradiation is not recommended (OUTBACK).","refs":["keynote-a18","pembrolizumab","interlace","induction-chemo-then-crt","io-plus-crt-cervical","outback"],"guideline":{"nccn":"1 (pembrolizumab); 2A (induction)","esmoMcbs":"A (KEYNOTE-A18)"}},{"setting":"Persistent, recurrent, or metastatic, first line","approach":"Pembrolizumab + cisplatin/carboplatin-paclitaxel ± bevacizumab (KEYNOTE-826, CPS ≥1 in the US); atezolizumab + chemotherapy + bevacizumab (BEATcc, region-dependent); cadonilimab + chemotherapy in China (COMPASSION-16).","refs":["keynote-826","pembrolizumab","bevacizumab","beatcc","atezolizumab","compassion-16","cadonilimab"],"guideline":{"nccn":"1","esmoMcbs":"4"}},{"setting":"Second line and beyond","approach":"Tisotumab vedotin (innovaTV 301, OS benefit); cemiplimab if immunotherapy-naive (EU); T-DXd for HER2 IHC 3+; pembrolizumab for MSI-H/TMB-high; single-agent chemotherapy; trials of sac-TMT and TIL therapy.","refs":["tisotumab-vedotin","innovatv-301","cemiplimab","empower-cervical-1","trastuzumab-deruxtecan","destiny-pantumor02","sacituzumab-tirumotecan","lifileucel"],"guideline":{"nccn":"1 (tisotumab)"}},{"setting":"Pelvic recurrence after radiation","approach":"Pelvic exenteration in selected patients with central recurrence; re-irradiation with brachytherapy or proton therapy in specialised centres.","refs":["robotic-surgery","brachytherapy","proton-therapy"],"guideline":{"nccn":"2A"}}],"stateOfArt":["Near-elimination in vaccinated cohorts (Scotland, Sweden).","IO in locally advanced and metastatic disease.","Vaccinated cohorts in Sweden and Scotland show a ~90% to near-total reduction in invasive cervical cancer; single-dose schedules (97.5% efficacy in KEN SHE) make global coverage achievable.","HPV primary screening with self-sampling has replaced the Pap smear as the recommended test and reaches women who never attended clinics.","Two curative-intent advances in one year after 24 years of stasis: induction chemotherapy (INTERLACE, OS HR 0.60) and pembrolizumab with chemoradiation (KEYNOTE-A18, OS HR 0.67).","First-line chemo-immunotherapy roughly doubles median survival in metastatic disease compared with the pre-2014 era (KEYNOTE-826 26.4 months; BEATcc 32.1 months).","The first ADC with survival benefit in cervical cancer (tisotumab vedotin) and tumour-agnostic HER2 ADC access.","Surgical evidence now favours less: simple over radical hysterectomy for small tumours (SHAPE) and open over minimally invasive radical hysterectomy (LACC)."],"history":[{"year":1943,"title":"Pap smear introduced","refs":[]},{"year":1943,"title":"Papanicolaou smear introduced","note":"Cytology screening cuts cervical cancer mortality by ~70% where implemented.","refs":[]},{"year":1983,"title":"zur Hausen identifies HPV16 in cervical cancer","note":"HPV18 follows in 1984; Nobel Prize 2008.","refs":["dkfz","hpv-vaccine"]},{"year":1999,"title":"NCI clinical alert: cisplatin with radiation","note":"Five randomised trials show 30-50% mortality reduction; chemoradiation becomes standard for locally advanced disease.","refs":["cisplatin","imrt-igrt"]},{"year":2006,"title":"HPV vaccine approved","refs":["hpv-vaccine"]},{"year":2006,"title":"First HPV vaccine (Gardasil) approved","refs":["gardasil-9","hpv-vaccine"]},{"year":2014,"title":"Bevacizumab extends survival in advanced disease (GOG-0240); Gardasil 9 approved; HPV primary screening approved in the US","refs":["bevacizumab","gardasil-9","hpv-testing"]},{"year":2018,"title":"LACC: minimally invasive radical hysterectomy is inferior","note":"Practice reverses to open surgery within months.","refs":["lacc"]},{"year":2020,"title":"WHO launches the Cervical Cancer Elimination Initiative (90-70-90 by 2030)","note":"Swedish registry study shows ~88% cancer reduction in women vaccinated before 17.","refs":["hpv-vaccine","hpv-testing"]},{"year":2021,"title":"Tisotumab vedotin approved","refs":["tisotumab-vedotin"]},{"year":2021,"title":"KEYNOTE-826: first-line chemo-immunotherapy; tisotumab vedotin accelerated approval; EMPOWER-Cervical 1","refs":["keynote-826","tisotumab-vedotin","empower-cervical-1"]},{"year":2022,"title":"WHO endorses single-dose HPV vaccination (KEN SHE); OUTBACK negative","refs":["ken-she","outback"]},{"year":2023,"title":"KEYNOTE-A18 and INTERLACE positive; BEATcc and innovaTV 301 positive","note":"Four practice-changing phase 3 results presented at ESMO 2023.","refs":["keynote-a18","interlace","beatcc","innovatv-301"]},{"year":2024,"title":"Pembrolizumab approved with chemoradiation (Jan); tisotumab full approval (Apr); FDA approves HPV self-collection (May); COMPASSION-16 published; SHAPE trial supports simple hysterectomy; Scotland reports zero cancers in fully vaccinated cohort","refs":["keynote-a18","tisotumab-vedotin","hpv-testing","compassion-16"]},{"year":2025,"title":"At-home HPV self-test approved in the US; single-dose schedules adopted by 60+ countries","refs":["hpv-testing","gardasil-9"]},{"year":2026,"title":"World Health Assembly calls for accountable elimination systems; sac-TMT and TIL trials in recurrent disease","refs":["sacituzumab-tirumotecan","lifileucel"]}],"pipeline":["sacituzumab-tirumotecan","lifileucel","shr-8068","shr-a2102","yl202","hlx43","gotistobart","hmbd-001","lorigerlimab","vudalimab","np137","cadonilimab","trastuzumab-deruxtecan","senticol-iii","hpv-testing","precancer-ablation","idea-single-dose-hpv-self-sampling-elimination","idea-hpv-ctdna-cervical","gardasil-9","mrd-testing","proton-therapy"],"openProblems":["Vaccine and screening access in LMICs.","Brachytherapy capacity.","Delivery, not discovery: the disease is preventable, yet global HPV vaccination coverage of girls is around 27% and 350,000 women still die of it each year.","Screening reaches under 30% of women in most low- and middle-income countries; brachytherapy capacity is absent in much of Africa.","Pembrolizumab with chemoradiation costs far more than induction chemotherapy; how to combine or choose between KEYNOTE-A18 and INTERLACE is untested.","Recurrent disease after chemo-immunotherapy has few options; tisotumab adds two months of median survival.","HPV-independent (gastric-type) adenocarcinoma and neuroendocrine carcinoma have poor outcomes and no specific therapy.","Minimally invasive surgery's harm mechanism is unresolved; protective-technique trials (RACC, ROCC) are pending.","Therapeutic HPV vaccines (E6/E7-directed) have repeatedly shown immunogenicity without clear clinical benefit in invasive cancer.","Fertility preservation options for tumours over 2 cm remain limited."],"prognosis":{"text":"In the United States, 68.8% of women diagnosed with cervical cancer in 2016-2022 were alive five years later, relative to women of the same age without the disease. 41% of cases are found while confined to the cervix, with five-year relative survival of 91.8%; it is 64% for regional disease (37% of cases) and 20.5% for distant disease (16% of cases). Screening and HPV vaccination prevent most cases altogether, which is why the outlook depends so heavily on where a woman lives.","sources":[{"label":"SEER Cancer Stat Facts: Cervical Cancer","url":"https://seer.cancer.gov/statfacts/html/cervix.html"}]}},"route":"/cancers/cervical/","neighbours":{"pairing":[{"id":"caution-mis-radical-hysterectomy","kind":"pairing","name":"Caution: minimally invasive radical hysterectomy for early cervical cancer","route":"/pairings/caution-mis-radical-hysterectomy/"},{"id":"induction-chemo-then-crt","kind":"pairing","name":"Induction chemotherapy → chemoradiation (locally advanced cervical cancer)","route":"/pairings/induction-chemo-then-crt/"},{"id":"io-plus-crt-cervical","kind":"pairing","name":"PD-1 blockade + chemoradiation (locally advanced cervical cancer)","route":"/pairings/io-plus-crt-cervical/"},{"id":"radiation-plus-io","kind":"pairing","name":"Radiotherapy + immunotherapy","route":"/pairings/radiation-plus-io/"}],"roadmap":[{"id":"early-detection-roadmap","kind":"roadmap","name":"Early detection roadmap: organ screening → blood tests for many cancers","route":"/roadmaps/early-detection-roadmap/"}],"cancer":[{"id":"cervical-adenosquamous-carcinoma","kind":"cancer","name":"Adenosquamous carcinoma of the cervix","route":"/cancers/cervical-adenosquamous-carcinoma/"},{"id":"aya-cancers","kind":"cancer","name":"Adolescent and young adult cancers (ages 15 to 39)","route":"/cancers/aya-cancers/"},{"id":"early-cervical-cancer","kind":"cancer","name":"Early cervical cancer and fertility-sparing surgery","route":"/cancers/early-cervical-cancer/"},{"id":"locally-advanced-cervical-cancer","kind":"cancer","name":"Locally advanced cervical cancer","route":"/cancers/locally-advanced-cervical-cancer/"},{"id":"penile","kind":"cancer","name":"Penile cancer","route":"/cancers/penile/"},{"id":"recurrent-metastatic-cervical-cancer","kind":"cancer","name":"Recurrent or metastatic cervical cancer","route":"/cancers/recurrent-metastatic-cervical-cancer/"},{"id":"cervical-small-cell-neuroendocrine-carcinoma","kind":"cancer","name":"Small cell neuroendocrine carcinoma of the cervix","route":"/cancers/cervical-small-cell-neuroendocrine-carcinoma/"},{"id":"vaginal","kind":"cancer","name":"Vaginal cancer","route":"/cancers/vaginal/"}],"technology":[{"id":"rejuv-access-survivorship-care-lmic","kind":"technology","name":"After treatment in low and middle income countries: mostly nothing","route":"/technologies/rejuv-access-survivorship-care-lmic/"},{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"bacterial-vector-vaccines","kind":"technology","name":"Bacterial vector cancer vaccines","route":"/technologies/bacterial-vector-vaccines/"},{"id":"bowel-after-pelvic-radiotherapy","kind":"technology","name":"Bowel function after pelvic radiotherapy","route":"/technologies/bowel-after-pelvic-radiotherapy/"},{"id":"brachytherapy","kind":"technology","name":"Brachytherapy","route":"/technologies/brachytherapy/"},{"id":"c-arm-linac","kind":"technology","name":"C-arm medical linear accelerators (TrueBeam, Versa HD and others)","route":"/technologies/c-arm-linac/"},{"id":"rejuv-life-children-of-a-parent-with-cancer","kind":"technology","name":"Children of a parent treated for cancer","route":"/technologies/rejuv-life-children-of-a-parent-with-cancer/"},{"id":"colposcopes-digital-cervical-screening","kind":"technology","name":"Colposcopes and digital cervical screening devices (DYSIS, EVA System, AVE)","route":"/technologies/colposcopes-digital-cervical-screening/"},{"id":"colposcopy-excision","kind":"technology","name":"Colposcopy and excisional treatment (LEEP/LLETZ, cone)","route":"/technologies/colposcopy-excision/"},{"id":"global-oncology-access","kind":"technology","name":"Global oncology and access in low- and middle-income countries","route":"/technologies/global-oncology-access/"},{"id":"hand-held-ultrasound","kind":"technology","name":"Hand-held and point-of-care ultrasound","route":"/technologies/hand-held-ultrasound/"},{"id":"hdr-brachytherapy","kind":"technology","name":"High-dose-rate brachytherapy","route":"/technologies/hdr-brachytherapy/"},{"id":"hpv-vaccine","kind":"technology","name":"HPV & HBV vaccination","route":"/technologies/hpv-vaccine/"},{"id":"hpv-testing","kind":"technology","name":"HPV DNA testing and self-sampling","route":"/technologies/hpv-testing/"},{"id":"hyperbaric-oxygen-radiation-injury","kind":"technology","name":"Hyperbaric oxygen for late radiation injury","route":"/technologies/hyperbaric-oxygen-radiation-injury/"},{"id":"hyperthermia","kind":"technology","name":"Hyperthermia","route":"/technologies/hyperthermia/"},{"id":"hyperthermia-systems","kind":"technology","name":"Hyperthermia systems (BSD-2000, EHY-2000, superficial and interstitial applicators)","route":"/technologies/hyperthermia-systems/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"},{"id":"in-room-imaging-systems","kind":"technology","name":"In-room imaging for radiotherapy (cone-beam CT, ExacTrac, CT-on-rails, HyperSight)","route":"/technologies/in-room-imaging-systems/"},{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"lymphoedema-surgery-and-early-detection","kind":"technology","name":"Lymphoedema: catching it early, and the operations for it","route":"/technologies/lymphoedema-surgery-and-early-detection/"},{"id":"rejuv-measure-lymphoedema","kind":"technology","name":"Measuring lymphoedema: tape, bioimpedance and the quality of life scales","route":"/technologies/rejuv-measure-lymphoedema/"},{"id":"menopause-after-cancer-treatment","kind":"technology","name":"Menopause brought on by cancer treatment, and the options for it","route":"/technologies/menopause-after-cancer-treatment/"},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"},{"id":"fertility-preservation","kind":"technology","name":"Oncofertility and fertility preservation","route":"/technologies/fertility-preservation/"},{"id":"ovarian-function-after-chemotherapy","kind":"technology","name":"Ovarian function after chemotherapy: who recovers, and when","route":"/technologies/ovarian-function-after-chemotherapy/"},{"id":"rejuv-rehab-pelvic-floor","kind":"technology","name":"Pelvic floor rehabilitation after prostate and rectal surgery and after pelvic radiotherapy","route":"/technologies/rejuv-rehab-pelvic-floor/"},{"id":"probiotics-treatment-diarrhoea","kind":"technology","name":"Probiotics for chemotherapy and radiotherapy diarrhoea","route":"/technologies/probiotics-treatment-diarrhoea/"},{"id":"proton-therapy","kind":"technology","name":"Proton therapy","route":"/technologies/proton-therapy/"},{"id":"radiosensitisers","kind":"technology","name":"Radiosensitisers","route":"/technologies/radiosensitisers/"},{"id":"rejuv-recon-pelvic-exenteration","kind":"technology","name":"Recovery after pelvic exenteration","route":"/technologies/rejuv-recon-pelvic-exenteration/"},{"id":"brachytherapy-afterloaders","kind":"technology","name":"Remote afterloaders for HDR brachytherapy","route":"/technologies/brachytherapy-afterloaders/"},{"id":"ring-gantry-linac","kind":"technology","name":"Ring-gantry linacs (Halcyon, Ethos)","route":"/technologies/ring-gantry-linac/"},{"id":"robotic-surgery","kind":"technology","name":"Robotic & minimally invasive surgery","route":"/technologies/robotic-surgery/"},{"id":"sentinel-node","kind":"technology","name":"Sentinel lymph node biopsy","route":"/technologies/sentinel-node/"},{"id":"sexual-function-after-cancer","kind":"technology","name":"Sexual function and intimacy after cancer, for both sexes","route":"/technologies/sexual-function-after-cancer/"},{"id":"smoking-cessation-after-diagnosis","kind":"technology","name":"Smoking cessation in cancer patients","route":"/technologies/smoking-cessation-after-diagnosis/"},{"id":"fractionation-repopulation-models","kind":"technology","name":"The four Rs and accelerated repopulation","route":"/technologies/fractionation-repopulation-models/"},{"id":"precancer-ablation","kind":"technology","name":"Thermal ablation and cryotherapy for cervical precancer","route":"/technologies/precancer-ablation/"},{"id":"til-therapy","kind":"technology","name":"TIL therapy","route":"/technologies/til-therapy/"},{"id":"tumour-hypoxia-modification","kind":"technology","name":"Tumour hypoxia: imaging and modification","route":"/technologies/tumour-hypoxia-modification/"},{"id":"vaginal-oestrogen-after-breast-cancer","kind":"technology","name":"Vaginal oestrogen after breast cancer: what the evidence says, and where it disagrees","route":"/technologies/vaginal-oestrogen-after-breast-cancer/"},{"id":"via-cervical-screening","kind":"technology","name":"Visual inspection with acetic acid (VIA) for cervical screening","route":"/technologies/via-cervical-screening/"},{"id":"rejuv-access-what-it-costs-elsewhere","kind":"technology","name":"What recovery costs in the rest of the world","route":"/technologies/rejuv-access-what-it-costs-elsewhere/"},{"id":"rejuv-access-fertility-preservation","kind":"technology","name":"Who gets told about fertility before treatment, and who does not","route":"/technologies/rejuv-access-fertility-preservation/"},{"id":"rejuv-access-who-misses-out","kind":"technology","name":"Who misses out on recovery care, measured","route":"/technologies/rejuv-access-who-misses-out/"}],"target":[{"id":"arid1b","kind":"target","name":"ARID1B","route":"/targets/arid1b/"},{"id":"b2m","kind":"target","name":"B2M","route":"/targets/b2m/"},{"id":"bap1","kind":"target","name":"BAP1","route":"/targets/bap1/"},{"id":"casp8","kind":"target","name":"CASP8","route":"/targets/casp8/"},{"id":"cd44","kind":"target","name":"CD44","route":"/targets/cd44/"},{"id":"cdk12","kind":"target","name":"CDK12","route":"/targets/cdk12/"},{"id":"clip1","kind":"target","name":"CLIP1","route":"/targets/clip1/"},{"id":"ctla4","kind":"target","name":"CTLA-4","route":"/targets/ctla4/"},{"id":"ctnna1","kind":"target","name":"CTNNA1","route":"/targets/ctnna1/"},{"id":"cysltr2","kind":"target","name":"CYSLTR2","route":"/targets/cysltr2/"},{"id":"eif3e","kind":"target","name":"EIF3E","route":"/targets/eif3e/"},{"id":"ep300","kind":"target","name":"EP300","route":"/targets/ep300/"},{"id":"ercc3","kind":"target","name":"ERCC3","route":"/targets/ercc3/"},{"id":"fas","kind":"target","name":"FAS","route":"/targets/fas/"},{"id":"fat1","kind":"target","name":"FAT1","route":"/targets/fat1/"},{"id":"fbxw7","kind":"target","name":"FBXW7","route":"/targets/fbxw7/"},{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"},{"id":"hla-b","kind":"target","name":"HLA-B","route":"/targets/hla-b/"},{"id":"klf5","kind":"target","name":"KLF5","route":"/targets/klf5/"},{"id":"lats1","kind":"target","name":"LATS1","route":"/targets/lats1/"},{"id":"map3k1","kind":"target","name":"MAP3K1","route":"/targets/map3k1/"},{"id":"mapk1","kind":"target","name":"MAPK1","route":"/targets/mapk1/"},{"id":"mcm7","kind":"target","name":"MCM7","route":"/targets/mcm7/"},{"id":"med12","kind":"target","name":"MED12","route":"/targets/med12/"},{"id":"nbea","kind":"target","name":"NBEA","route":"/targets/nbea/"},{"id":"nf2","kind":"target","name":"NF2","route":"/targets/nf2/"},{"id":"nfe2l2","kind":"target","name":"NFE2L2","route":"/targets/nfe2l2/"},{"id":"notch1","kind":"target","name":"NOTCH1","route":"/targets/notch1/"},{"id":"nsd1","kind":"target","name":"NSD1","route":"/targets/nsd1/"},{"id":"pbrm1","kind":"target","name":"PBRM1","route":"/targets/pbrm1/"},{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"},{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/"},{"id":"sirpa","kind":"target","name":"SIRPA","route":"/targets/sirpa/"},{"id":"snd1","kind":"target","name":"SND1","route":"/targets/snd1/"},{"id":"spen","kind":"target","name":"SPEN","route":"/targets/spen/"},{"id":"sphk1","kind":"target","name":"SPHK1","route":"/targets/sphk1/"},{"id":"stk11","kind":"target","name":"STK11","route":"/targets/stk11/"},{"id":"tgfbr2","kind":"target","name":"TGFBR2","route":"/targets/tgfbr2/"},{"id":"tissue-factor","kind":"target","name":"Tissue factor","route":"/targets/tissue-factor/"},{"id":"tp63","kind":"target","name":"TP63","route":"/targets/tp63/"},{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"},{"id":"tuba1a","kind":"target","name":"TUBA1A","route":"/targets/tuba1a/"},{"id":"tuba1b","kind":"target","name":"TUBA1B","route":"/targets/tuba1b/"},{"id":"tuba1c","kind":"target","name":"TUBA1C","route":"/targets/tuba1c/"},{"id":"tuba3c","kind":"target","name":"TUBA3C","route":"/targets/tuba3c/"},{"id":"tuba3e","kind":"target","name":"TUBA3E","route":"/targets/tuba3e/"},{"id":"tuba4a","kind":"target","name":"TUBA4A","route":"/targets/tuba4a/"},{"id":"tubb1","kind":"target","name":"TUBB1","route":"/targets/tubb1/"},{"id":"tubb2a","kind":"target","name":"TUBB2A","route":"/targets/tubb2a/"},{"id":"tubb2b","kind":"target","name":"TUBB2B","route":"/targets/tubb2b/"},{"id":"tubb3","kind":"target","name":"TUBB3","route":"/targets/tubb3/"},{"id":"tubb4a","kind":"target","name":"TUBB4A","route":"/targets/tubb4a/"},{"id":"tubb4b","kind":"target","name":"TUBB4B","route":"/targets/tubb4b/"},{"id":"tubb6","kind":"target","name":"TUBB6","route":"/targets/tubb6/"},{"id":"tubb8","kind":"target","name":"TUBB8","route":"/targets/tubb8/"},{"id":"vegf","kind":"target","name":"VEGF / VEGFR","route":"/targets/vegf/"},{"id":"xrcc1","kind":"target","name":"XRCC1","route":"/targets/xrcc1/"},{"id":"znf521","kind":"target","name":"ZNF521","route":"/targets/znf521/"}],"company":[{"id":"akeso","kind":"company","name":"Akeso","route":"/companies/akeso/"},{"id":"ananya-health","kind":"company","name":"Ananya Health","route":"/companies/ananya-health/"},{"id":"arcagy-gineco","kind":"company","name":"ARCAGY-GINECO","route":"/companies/arcagy-gineco/"},{"id":"bio-thera-solutions","kind":"company","name":"Bio-Thera Solutions","route":"/companies/bio-thera-solutions/"},{"id":"color-health","kind":"company","name":"Color Health","route":"/companies/color-health/"},{"id":"dysis-medical","kind":"company","name":"DYSIS Medical","route":"/companies/dysis-medical/"},{"id":"eurofarma","kind":"company","name":"Eurofarma","route":"/companies/eurofarma/"},{"id":"evopoint-biosciences","kind":"company","name":"Evopoint Biosciences","route":"/companies/evopoint-biosciences/"},{"id":"genmab","kind":"company","name":"Genmab","route":"/companies/genmab/"},{"id":"gi-innovation","kind":"company","name":"GI Innovation","route":"/companies/gi-innovation/"},{"id":"gog-foundation","kind":"company","name":"GOG Foundation","route":"/companies/gog-foundation/"},{"id":"grit-bio","kind":"company","name":"Grit Bio","route":"/companies/grit-bio/"},{"id":"hologic","kind":"company","name":"Hologic","route":"/companies/hologic/"},{"id":"inovio","kind":"company","name":"Inovio Pharmaceuticals","route":"/companies/inovio/"},{"id":"mabwell-shanghai-bioscience","kind":"company","name":"Mabwell (Shanghai) Bioscience","route":"/companies/mabwell-shanghai-bioscience/"},{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"},{"id":"mobileodt","kind":"company","name":"MobileODT","route":"/companies/mobileodt/"},{"id":"modex-therapeutics","kind":"company","name":"ModeX Therapeutics","route":"/companies/modex-therapeutics/"},{"id":"neonc-technologies","kind":"company","name":"Neonc Technologies","route":"/companies/neonc-technologies/"},{"id":"nrg-oncology","kind":"company","name":"NRG Oncology","route":"/companies/nrg-oncology/"},{"id":"nykode-therapeutics","kind":"company","name":"Nykode Therapeutics","route":"/companies/nykode-therapeutics/"},{"id":"pfizer","kind":"company","name":"Pfizer (incl. Seagen)","route":"/companies/pfizer/"},{"id":"precigen","kind":"company","name":"Precigen","route":"/companies/precigen/"},{"id":"pyrexar-medical","kind":"company","name":"Pyrexar Medical","route":"/companies/pyrexar-medical/"},{"id":"qurient","kind":"company","name":"Qurient","route":"/companies/qurient/"},{"id":"radiopharm-theranostics","kind":"company","name":"Radiopharm Theranostics","route":"/companies/radiopharm-theranostics/"},{"id":"regeneron","kind":"company","name":"Regeneron","route":"/companies/regeneron/"},{"id":"roche-genentech","kind":"company","name":"Roche / Genentech","route":"/companies/roche-genentech/"},{"id":"serum-institute-of-india","kind":"company","name":"Serum Institute of India","route":"/companies/serum-institute-of-india/"},{"id":"shanghai-bovax-biotechnology","kind":"company","name":"Shanghai Bovax Biotechnology","route":"/companies/shanghai-bovax-biotechnology/"},{"id":"simcere","kind":"company","name":"Simcere Pharmaceutical","route":"/companies/simcere/"}],"institution":[{"id":"actrec","kind":"institution","name":"Advanced Centre for Treatment, Research and Education in Cancer","route":"/institutions/actrec/"},{"id":"aga-khan-university-hospital-nairobi","kind":"institution","name":"Aga Khan University Hospital, Nairobi","route":"/institutions/aga-khan-university-hospital-nairobi/"},{"id":"aiims-delhi","kind":"institution","name":"All India Institute of Medical Sciences, New Delhi","route":"/institutions/aiims-delhi/"},{"id":"bc-cancer","kind":"institution","name":"BC Cancer","route":"/institutions/bc-cancer/"},{"id":"butaro-cancer-center","kind":"institution","name":"Butaro Cancer Center of Excellence","route":"/institutions/butaro-cancer-center/"},{"id":"cancer-council-australia","kind":"institution","name":"Cancer Council Australia","route":"/institutions/cancer-council-australia/"},{"id":"cancer-diseases-hospital-lusaka","kind":"institution","name":"Cancer Diseases Hospital, Lusaka","route":"/institutions/cancer-diseases-hospital-lusaka/"},{"id":"cancer-institute-adyar","kind":"institution","name":"Cancer Institute (WIA), Adyar","route":"/institutions/cancer-institute-adyar/"},{"id":"cruk","kind":"institution","name":"Cancer Research UK","route":"/institutions/cruk/"},{"id":"ico-catalonia","kind":"institution","name":"Catalan Institute of Oncology (ICO)","route":"/institutions/ico-catalonia/"},{"id":"centre-oscar-lambret","kind":"institution","name":"Centre Oscar Lambret","route":"/institutions/centre-oscar-lambret/"},{"id":"wits-charlotte-maxeke","kind":"institution","name":"Charlotte Maxeke Johannesburg Academic Hospital / University of the Witwatersrand","route":"/institutions/wits-charlotte-maxeke/"},{"id":"chulabhorn-hospital","kind":"institution","name":"Chulabhorn Hospital / Chulabhorn Royal Academy","route":"/institutions/chulabhorn-hospital/"},{"id":"dharmais-cancer-hospital","kind":"institution","name":"Dharmais National Cancer Center","route":"/institutions/dharmais-cancer-hospital/"},{"id":"esgo","kind":"institution","name":"European Society of Gynaecological Oncology","route":"/institutions/esgo/"},{"id":"gates-foundation","kind":"institution","name":"Gates Foundation","route":"/institutions/gates-foundation/"},{"id":"dkfz","kind":"institution","name":"German Cancer Research Center (DKFZ)","route":"/institutions/dkfz/"},{"id":"groote-schuur-uct","kind":"institution","name":"Groote Schuur Hospital / University of Cape Town","route":"/institutions/groote-schuur-uct/"},{"id":"hacettepe-cancer-institute","kind":"institution","name":"Hacettepe University Cancer Institute","route":"/institutions/hacettepe-cancer-institute/"},{"id":"hcg","kind":"institution","name":"HealthCare Global Enterprises","route":"/institutions/hcg/"},{"id":"hcmc-oncology-hospital","kind":"institution","name":"Ho Chi Minh City Oncology Hospital","route":"/institutions/hcmc-oncology-hospital/"},{"id":"homi-bhabha-cancer-hospital-varanasi","kind":"institution","name":"Homi Bhabha Cancer Hospital and Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Varanasi","route":"/institutions/homi-bhabha-cancer-hospital-varanasi/"},{"id":"hospital-de-amor-barretos","kind":"institution","name":"Hospital de Amor (Barretos Cancer Hospital)","route":"/institutions/hospital-de-amor-barretos/"},{"id":"houston-methodist-neal-cancer-center","kind":"institution","name":"Houston Methodist Dr. Mary and Ron Neal Cancer Center","route":"/institutions/houston-methodist-neal-cancer-center/"},{"id":"hunan-cancer-hospital","kind":"institution","name":"Hunan Cancer Hospital","route":"/institutions/hunan-cancer-hospital/"},{"id":"icmr-nicpr","kind":"institution","name":"ICMR-National Institute of Cancer Prevention and Research","route":"/institutions/icmr-nicpr/"},{"id":"inkosi-albert-luthuli-hospital","kind":"institution","name":"Inkosi Albert Luthuli Central Hospital","route":"/institutions/inkosi-albert-luthuli-hospital/"},{"id":"institut-national-oncologie-rabat","kind":"institution","name":"Institut National d'Oncologie, Rabat","route":"/institutions/institut-national-oncologie-rabat/"},{"id":"institut-pasteur","kind":"institution","name":"Institut Pasteur","route":"/institutions/institut-pasteur/"},{"id":"institut-salah-azaiez","kind":"institution","name":"Institut Salah Azaïez","route":"/institutions/institut-salah-azaiez/"},{"id":"inca-brazil","kind":"institution","name":"Instituto Nacional de Câncer (INCA)","route":"/institutions/inca-brazil/"},{"id":"inc-colombia","kind":"institution","name":"Instituto Nacional de Cancerología (Colombia)","route":"/institutions/inc-colombia/"},{"id":"incan-mexico","kind":"institution","name":"Instituto Nacional de Cancerología (Mexico)","route":"/institutions/incan-mexico/"},{"id":"inen-peru","kind":"institution","name":"Instituto Nacional de Enfermedades Neoplásicas","route":"/institutions/inen-peru/"},{"id":"iarc","kind":"institution","name":"International Agency for Research on Cancer (IARC / WHO)","route":"/institutions/iarc/"},{"id":"iuct-oncopole","kind":"institution","name":"IUCT Oncopole (Institut Universitaire du Cancer de Toulouse)","route":"/institutions/iuct-oncopole/"},{"id":"kaiser-permanente-research","kind":"institution","name":"Kaiser Permanente Division of Research","route":"/institutions/kaiser-permanente-research/"},{"id":"kenyatta-national-hospital","kind":"institution","name":"Kenyatta National Hospital","route":"/institutions/kenyatta-national-hospital/"},{"id":"kidwai-memorial-institute-of-oncology","kind":"institution","name":"Kidwai Memorial Institute of Oncology","route":"/institutions/kidwai-memorial-institute-of-oncology/"},{"id":"komfo-anokye-teaching-hospital","kind":"institution","name":"Komfo Anokye Teaching Hospital","route":"/institutions/komfo-anokye-teaching-hospital/"},{"id":"korle-bu-teaching-hospital","kind":"institution","name":"Korle Bu Teaching Hospital","route":"/institutions/korle-bu-teaching-hospital/"},{"id":"luth-lagos","kind":"institution","name":"Lagos University Teaching Hospital","route":"/institutions/luth-lagos/"},{"id":"lumc-leiden","kind":"institution","name":"Leiden University Medical Center","route":"/institutions/lumc-leiden/"},{"id":"kentucky-markey","kind":"institution","name":"Markey Cancer Center, University of Kentucky","route":"/institutions/kentucky-markey/"},{"id":"md-anderson","kind":"institution","name":"MD Anderson Cancer Center","route":"/institutions/md-anderson/"},{"id":"moi-teaching-referral-hospital","kind":"institution","name":"Moi Teaching and Referral Hospital / AMPATH Oncology","route":"/institutions/moi-teaching-referral-hospital/"},{"id":"icmr-ncrp","kind":"institution","name":"National Cancer Registry Programme (ICMR-NINE, Bengaluru)","route":"/institutions/icmr-ncrp/"},{"id":"nci-ccr","kind":"institution","name":"NCI Center for Cancer Research (intramural programme)","route":"/institutions/nci-ccr/"},{"id":"ocean-road-cancer-institute","kind":"institution","name":"Ocean Road Cancer Institute","route":"/institutions/ocean-road-cancer-institute/"},{"id":"pumch","kind":"institution","name":"Peking Union Medical College Hospital","route":"/institutions/pumch/"},{"id":"philippine-general-hospital","kind":"institution","name":"Philippine General Hospital","route":"/institutions/philippine-general-hospital/"},{"id":"gemelli","kind":"institution","name":"Policlinico Universitario A. Gemelli","route":"/institutions/gemelli/"},{"id":"pgimer-chandigarh","kind":"institution","name":"Postgraduate Institute of Medical Education and Research, Chandigarh","route":"/institutions/pgimer-chandigarh/"},{"id":"rgci","kind":"institution","name":"Rajiv Gandhi Cancer Institute and Research Centre","route":"/institutions/rgci/"},{"id":"rutgers-cinj","kind":"institution","name":"Rutgers Cancer Institute of New Jersey","route":"/institutions/rutgers-cinj/"},{"id":"sgo","kind":"institution","name":"Society of Gynecologic Oncology","route":"/institutions/sgo/"},{"id":"stephenson-oklahoma","kind":"institution","name":"Stephenson Cancer Center, OU Health","route":"/institutions/stephenson-oklahoma/"},{"id":"tata-memorial","kind":"institution","name":"Tata Memorial Centre","route":"/institutions/tata-memorial/"},{"id":"uq-frazer-institute","kind":"institution","name":"The University of Queensland Frazer Institute","route":"/institutions/uq-frazer-institute/"},{"id":"tikur-anbessa-hospital","kind":"institution","name":"Tikur Anbessa Specialized Hospital, Addis Ababa University","route":"/institutions/tikur-anbessa-hospital/"},{"id":"tongji-hospital-wuhan","kind":"institution","name":"Tongji Hospital, Huazhong University of Science and Technology","route":"/institutions/tongji-hospital-wuhan/"},{"id":"tygerberg-hospital","kind":"institution","name":"Tygerberg Hospital / Stellenbosch University","route":"/institutions/tygerberg-hospital/"},{"id":"uganda-cancer-institute","kind":"institution","name":"Uganda Cancer Institute","route":"/institutions/uganda-cancer-institute/"},{"id":"unm-cancer-center","kind":"institution","name":"University of New Mexico Comprehensive Cancer Center","route":"/institutions/unm-cancer-center/"},{"id":"uz-leuven","kind":"institution","name":"UZ Leuven / Leuven Cancer Institute","route":"/institutions/uz-leuven/"},{"id":"k-hospital-hanoi","kind":"institution","name":"Vietnam National Cancer Hospital (K Hospital)","route":"/institutions/k-hospital-hanoi/"},{"id":"who","kind":"institution","name":"World Health Organization Cancer Programme","route":"/institutions/who/"},{"id":"zhejiang-cancer-hospital","kind":"institution","name":"Zhejiang Cancer Hospital","route":"/institutions/zhejiang-cancer-hospital/"}],"term":[{"id":"second-primary-bowel-after-abdominal-radiotherapy","kind":"term","name":"Bowel cancer after abdominal and pelvic radiotherapy","route":"/terms/second-primary-bowel-after-abdominal-radiotherapy/"},{"id":"brachytherapy-term","kind":"term","name":"Brachytherapy (internal radiotherapy)","route":"/terms/brachytherapy-term/"},{"id":"cancer-in-pregnancy","kind":"term","name":"Cancer during pregnancy","route":"/terms/cancer-in-pregnancy/"},{"id":"vaccines-and-oncolytic-viruses","kind":"term","name":"Cancer vaccines and oncolytic viruses","route":"/terms/vaccines-and-oncolytic-viruses/"},{"id":"carcinoma-in-situ","kind":"term","name":"Carcinoma in situ (CIS)","route":"/terms/carcinoma-in-situ/"},{"id":"cin-hsil","kind":"term","name":"Cervical precancer (CIN, HSIL/LSIL)","route":"/terms/cin-hsil/"},{"id":"chemoradiation","kind":"term","name":"Chemoradiation (chemoradiotherapy, CRT)","route":"/terms/chemoradiation/"},{"id":"cps","kind":"term","name":"Combined positive score (CPS)","route":"/terms/cps/"},{"id":"dysplasia","kind":"term","name":"Dysplasia (pre-cancerous change)","route":"/terms/dysplasia/"},{"id":"hpv-status","kind":"term","name":"HPV status (HPV-positive / HPV-negative)","route":"/terms/hpv-status/"},{"id":"hysterectomy","kind":"term","name":"Hysterectomy","route":"/terms/hysterectomy/"},{"id":"microenvironment-inflammation-theory","kind":"term","name":"Microenvironment and inflammation: tumours as wounds that do not heal","route":"/terms/microenvironment-inflammation-theory/"},{"id":"squamous-cell-carcinoma","kind":"term","name":"Squamous cell carcinoma","route":"/terms/squamous-cell-carcinoma/"},{"id":"tumour-agnostic","kind":"term","name":"Tumour-agnostic (tissue-agnostic) approval","route":"/terms/tumour-agnostic/"}],"trial":[{"id":"nct07189871","kind":"trial","name":"177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors","route":"/trials/nct07189871/"},{"id":"nct05086692","kind":"trial","name":"A Beta-only IL-2 ImmunoTherapY Study","route":"/trials/nct05086692/"},{"id":"nct07216703","kind":"trial","name":"A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Canc","route":"/trials/nct07216703/"},{"id":"nct07109726","kind":"trial","name":"A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations","route":"/trials/nct07109726/"},{"id":"nct06769152","kind":"trial","name":"A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors","route":"/trials/nct06769152/"},{"id":"nct07051486","kind":"trial","name":"A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer","route":"/trials/nct07051486/"},{"id":"nct07168200","kind":"trial","name":"A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the","route":"/trials/nct07168200/"},{"id":"nct05235516","kind":"trial","name":"A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer","route":"/trials/nct05235516/"},{"id":"nct07054567","kind":"trial","name":"A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer","route":"/trials/nct07054567/"},{"id":"nct05990803","kind":"trial","name":"A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies","route":"/trials/nct05990803/"},{"id":"nct04895709","kind":"trial","name":"A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors","route":"/trials/nct04895709/"},{"id":"nct05798819","kind":"trial","name":"A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervic","route":"/trials/nct05798819/"},{"id":"nct06172478","kind":"trial","name":"A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct06172478/"},{"id":"nct07602842","kind":"trial","name":"A Study of IDP-001 in Advanced or Metastatic Solid Tumors","route":"/trials/nct07602842/"},{"id":"nct06155396","kind":"trial","name":"A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent o","route":"/trials/nct06155396/"},{"id":"nct07418749","kind":"trial","name":"A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer","route":"/trials/nct07418749/"},{"id":"nct06943833","kind":"trial","name":"A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA)","route":"/trials/nct06943833/"},{"id":"nct05032040","kind":"trial","name":"A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies","route":"/trials/nct05032040/"},{"id":"nct07202364","kind":"trial","name":"A Study of YL202 in Patients With Advanced Solid Tumors","route":"/trials/nct07202364/"},{"id":"nct06459180","kind":"trial","name":"A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With","route":"/trials/nct06459180/"},{"id":"nct06692166","kind":"trial","name":"A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer","route":"/trials/nct06692166/"},{"id":"nct06319963","kind":"trial","name":"A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer","route":"/trials/nct06319963/"},{"id":"nct05081609","kind":"trial","name":"A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other","route":"/trials/nct05081609/"},{"id":"nct06241781","kind":"trial","name":"Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer","route":"/trials/nct06241781/"},{"id":"nct04579380","kind":"trial","name":"Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations","route":"/trials/nct04579380/"},{"id":"nct06123884","kind":"trial","name":"BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer","route":"/trials/nct06123884/"},{"id":"beatcc","kind":"trial","name":"BEATcc / ENGOT-Cx10 / GOG-3030","route":"/trials/beatcc/"},{"id":"calla","kind":"trial","name":"CALLA","route":"/trials/calla/"},{"id":"nct04906993","kind":"trial","name":"Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer","route":"/trials/nct04906993/"},{"id":"checkmate-358","kind":"trial","name":"CheckMate 358","route":"/trials/checkmate-358/"},{"id":"compassion-16","kind":"trial","name":"COMPASSION-16 / AK104-303","route":"/trials/compassion-16/"},{"id":"destiny-pantumor02","kind":"trial","name":"DESTINY-PanTumor02","route":"/trials/destiny-pantumor02/"},{"id":"nct06239194","kind":"trial","name":"Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors","route":"/trials/nct06239194/"},{"id":"empower-cervical-1","kind":"trial","name":"EMPOWER-Cervical 1 / GOG-3016 / ENGOT-cx9","route":"/trials/empower-cervical-1/"},{"id":"nct04422366","kind":"trial","name":"Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females","route":"/trials/nct04422366/"},{"id":"nct04977453","kind":"trial","name":"GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors","route":"/trials/nct04977453/"},{"id":"nct06265025","kind":"trial","name":"GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors","route":"/trials/nct06265025/"},{"id":"nct04652076","kind":"trial","name":"GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab","route":"/trials/nct04652076/"},{"id":"iarc-india-hpv-dose-study","kind":"trial","name":"IARC India HPV vaccine dose study (one, two or three doses)","route":"/trials/iarc-india-hpv-dose-study/"},{"id":"nct05027776","kind":"trial","name":"Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years","route":"/trials/nct05027776/"},{"id":"innovatv-301","kind":"trial","name":"innovaTV 301 / ENGOT-cx12 / GOG-3057","route":"/trials/innovatv-301/"},{"id":"interlace","kind":"trial","name":"INTERLACE","route":"/trials/interlace/"},{"id":"ken-she","kind":"trial","name":"KEN SHE (single-dose HPV vaccine)","route":"/trials/ken-she/"},{"id":"keynote-158","kind":"trial","name":"KEYNOTE-158","route":"/trials/keynote-158/"},{"id":"keynote-826","kind":"trial","name":"KEYNOTE-826","route":"/trials/keynote-826/"},{"id":"keynote-a18","kind":"trial","name":"KEYNOTE-A18 / ENGOT-cx11 / GOG-3047","route":"/trials/keynote-a18/"},{"id":"lacc","kind":"trial","name":"LACC (Laparoscopic Approach to Cervical Cancer)","route":"/trials/lacc/"},{"id":"nct06641635","kind":"trial","name":"Moderated Hypofractionated Online Adaptive Radiotherapy in Cervical Cancer","route":"/trials/nct06641635/"},{"id":"mumbai-via-screening","kind":"trial","name":"Mumbai VIA cervical screening trial (Tata Memorial)","route":"/trials/mumbai-via-screening/"},{"id":"nct05438420","kind":"trial","name":"Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors","route":"/trials/nct05438420/"},{"id":"osmanabad-hpv-screening","kind":"trial","name":"Osmanabad cervical screening trial (HPV testing vs cytology vs VIA)","route":"/trials/osmanabad-hpv-screening/"},{"id":"outback","kind":"trial","name":"OUTBACK / ANZGOG 0902 / GOG-0274","route":"/trials/outback/"},{"id":"patricia","kind":"trial","name":"PATRICIA","route":"/trials/patricia/"},{"id":"nct04152499","kind":"trial","name":"Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)","route":"/trials/nct04152499/"},{"id":"nct06459687","kind":"trial","name":"Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer","route":"/trials/nct06459687/"},{"id":"nct06157151","kind":"trial","name":"PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer","route":"/trials/nct06157151/"},{"id":"nct03668639","kind":"trial","name":"Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin","route":"/trials/nct03668639/"},{"id":"nct06047379","kind":"trial","name":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","route":"/trials/nct06047379/"},{"id":"senticol-iii","kind":"trial","name":"SENTICOL III","route":"/trials/senticol-iii/"},{"id":"shape","kind":"trial","name":"SHAPE (CCTG CX.5)","route":"/trials/shape/"},{"id":"nct06859775","kind":"trial","name":"SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer","route":"/trials/nct06859775/"},{"id":"nct03476681","kind":"trial","name":"Study of NEO-201 in Solid Tumors Expansion Cohorts","route":"/trials/nct03476681/"},{"id":"nct06535607","kind":"trial","name":"Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors","route":"/trials/nct06535607/"},{"id":"nct06079671","kind":"trial","name":"Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)","route":"/trials/nct06079671/"},{"id":"nct06799637","kind":"trial","name":"Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments","route":"/trials/nct06799637/"},{"id":"nct07080216","kind":"trial","name":"Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer","route":"/trials/nct07080216/"}],"person":[{"id":"ana-oaknin","kind":"person","name":"Ana Oaknin","route":"/people/ana-oaknin/"},{"id":"ilbawi-andre","kind":"person","name":"André Ilbawi","route":"/people/ilbawi-andre/"},{"id":"antonio-gonzalez-martin","kind":"person","name":"Antonio González-Martín","route":"/people/antonio-gonzalez-martin/"},{"id":"bill-gates","kind":"person","name":"Bill Gates","route":"/people/bill-gates/"},{"id":"bradley-monk","kind":"person","name":"Bradley J. Monk","route":"/people/bradley-monk/"},{"id":"denise-galloway","kind":"person","name":"Denise A. Galloway","route":"/people/denise-galloway/"},{"id":"domenica-lorusso","kind":"person","name":"Domenica Lorusso","route":"/people/domenica-lorusso/"},{"id":"douglas-lowy","kind":"person","name":"Douglas R. Lowy","route":"/people/douglas-lowy/"},{"id":"giovanni-scambia","kind":"person","name":"Giovanni Scambia","route":"/people/giovanni-scambia/"},{"id":"harald-zur-hausen","kind":"person","name":"Harald zur Hausen","route":"/people/harald-zur-hausen/"},{"id":"henrietta-lacks","kind":"person","name":"Henrietta Lacks","route":"/people/henrietta-lacks/"},{"id":"ian-frazer","kind":"person","name":"Ian Frazer","route":"/people/ian-frazer/"},{"id":"ignace-vergote","kind":"person","name":"Ignace Vergote","route":"/people/ignace-vergote/"},{"id":"jack-cuzick","kind":"person","name":"Jack Cuzick","route":"/people/jack-cuzick/"},{"id":"jade-goody","kind":"person","name":"Jade Goody","route":"/people/jade-goody/"},{"id":"jalid-sehouli","kind":"person","name":"Jalid Sehouli","route":"/people/jalid-sehouli/"},{"id":"jian-zhou","kind":"person","name":"Jian Zhou","route":"/people/jian-zhou/"},{"id":"krishnansu-tewari","kind":"person","name":"Krishnansu S. Tewari","route":"/people/krishnansu-tewari/"},{"id":"linda-mileshkin","kind":"person","name":"Linda Mileshkin","route":"/people/linda-mileshkin/"},{"id":"marie-plante","kind":"person","name":"Marie Plante","route":"/people/marie-plante/"},{"id":"mark-schiffman","kind":"person","name":"Mark Schiffman","route":"/people/mark-schiffman/"},{"id":"mark-suzman","kind":"person","name":"Mark Suzman","route":"/people/mark-suzman/"},{"id":"mary-mccormack","kind":"person","name":"Mary McCormack","route":"/people/mary-mccormack/"},{"id":"nicoletta-colombo","kind":"person","name":"Nicoletta Colombo","route":"/people/nicoletta-colombo/"},{"id":"nubia-munoz","kind":"person","name":"Nubia Muñoz","route":"/people/nubia-munoz/"},{"id":"basu-partha","kind":"person","name":"Partha Basu","route":"/people/basu-partha/"},{"id":"pedro-ramirez","kind":"person","name":"Pedro T. Ramirez","route":"/people/pedro-ramirez/"},{"id":"peter-sasieni","kind":"person","name":"Peter Sasieni","route":"/people/peter-sasieni/"},{"id":"remi-nout","kind":"person","name":"Remi A. Nout","route":"/people/remi-nout/"},{"id":"sankaranarayanan-rengaswamy","kind":"person","name":"Rengaswamy Sankaranarayanan","route":"/people/sankaranarayanan-rengaswamy/"},{"id":"sebastien-armanet","kind":"person","name":"Sébastien Armanet","route":"/people/sebastien-armanet/"},{"id":"shastri-surendra","kind":"person","name":"Surendra Shastri","route":"/people/shastri-surendra/"},{"id":"tedros-adhanom-ghebreyesus","kind":"person","name":"Tedros Adhanom Ghebreyesus","route":"/people/tedros-adhanom-ghebreyesus/"},{"id":"thomas-herzog","kind":"person","name":"Thomas Herzog","route":"/people/thomas-herzog/"},{"id":"trevor-mundel","kind":"person","name":"Trevor Mundel","route":"/people/trevor-mundel/"},{"id":"shanta-v","kind":"person","name":"V. Shanta","route":"/people/shanta-v/"}],"journal":[{"id":"international-journal-of-gynecological-cancer","kind":"journal","name":"International journal of gynecological cancer","route":"/journals/international-journal-of-gynecological-cancer/"},{"id":"journal-of-gynecologic-oncology","kind":"journal","name":"Journal of gynecologic oncology","route":"/journals/journal-of-gynecologic-oncology/"},{"id":"tumour-virus-research","kind":"journal","name":"Tumour virus research","route":"/journals/tumour-virus-research/"}],"drug":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"},{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"cadonilimab","kind":"drug","name":"Cadonilimab","route":"/drugs/cadonilimab/"},{"id":"cemiplimab","kind":"drug","name":"Cemiplimab","route":"/drugs/cemiplimab/"},{"id":"cervavac","kind":"drug","name":"CERVAVAC (quadrivalent HPV vaccine, India)","route":"/drugs/cervavac/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"gecacitinib","kind":"drug","name":"Gecacitinib","route":"/drugs/gecacitinib/"},{"id":"gotistobart","kind":"drug","name":"Gotistobart","route":"/drugs/gotistobart/"},{"id":"hlx43","kind":"drug","name":"HLX43","route":"/drugs/hlx43/"},{"id":"hmbd-001","kind":"drug","name":"HMBD-001","route":"/drugs/hmbd-001/"},{"id":"hpv-bivalent-vaccine","kind":"drug","name":"HPV bivalent vaccine (types 16 and 18)","route":"/drugs/hpv-bivalent-vaccine/"},{"id":"hpv-quadrivalent-vaccine","kind":"drug","name":"HPV quadrivalent vaccine (types 6, 11, 16 and 18)","route":"/drugs/hpv-quadrivalent-vaccine/"},{"id":"iparomlimab-tuvonralimab","kind":"drug","name":"Iparomlimab and tuvonralimab","route":"/drugs/iparomlimab-tuvonralimab/"},{"id":"lifileucel","kind":"drug","name":"Lifileucel","route":"/drugs/lifileucel/"},{"id":"lorigerlimab","kind":"drug","name":"Lorigerlimab","route":"/drugs/lorigerlimab/"},{"id":"nedaplatin","kind":"drug","name":"Nedaplatin","route":"/drugs/nedaplatin/"},{"id":"gardasil-9","kind":"drug","name":"Nonavalent HPV vaccine","route":"/drugs/gardasil-9/"},{"id":"np137","kind":"drug","name":"NP137","route":"/drugs/np137/"},{"id":"dako-pd-l1-22c3-pharmdx","kind":"drug","name":"PD-L1 IHC 22C3 pharmDx","route":"/drugs/dako-pd-l1-22c3-pharmdx/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"sacituzumab-tirumotecan","kind":"drug","name":"Sacituzumab tirumotecan","route":"/drugs/sacituzumab-tirumotecan/"},{"id":"shr-8068","kind":"drug","name":"SHR-8068","route":"/drugs/shr-8068/"},{"id":"shr-a2102","kind":"drug","name":"SHR-A2102","route":"/drugs/shr-a2102/"},{"id":"socazolimab","kind":"drug","name":"Socazolimab","route":"/drugs/socazolimab/"},{"id":"tisotumab-vedotin","kind":"drug","name":"Tisotumab vedotin","route":"/drugs/tisotumab-vedotin/"},{"id":"topotecan","kind":"drug","name":"Topotecan","route":"/drugs/topotecan/"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/"},{"id":"vudalimab","kind":"drug","name":"Vudalimab","route":"/drugs/vudalimab/"},{"id":"yl202","kind":"drug","name":"YL202","route":"/drugs/yl202/"},{"id":"zimberelimab","kind":"drug","name":"Zimberelimab","route":"/drugs/zimberelimab/"}],"idea":[{"id":"idea-fund-prevention-moonshot","kind":"idea","name":"A delivery-science moonshot for prevention we already own","route":"/ideas/idea-fund-prevention-moonshot/"},{"id":"idea-fund-global-cancer-fund","kind":"idea","name":"A Global Fund for cancer care in low- and middle-income countries","route":"/ideas/idea-fund-global-cancer-fund/"},{"id":"idea-acc-metronomic-lmic-platform-trial","kind":"idea","name":"A platform trial of very-low-cost metronomic chemotherapy in LMIC common cancers","route":"/ideas/idea-acc-metronomic-lmic-platform-trial/"},{"id":"idea-prev-lmic-five-cancer-methylation-test","kind":"idea","name":"A ten-dollar blood test for the five cancers that kill most people in poorer countries","route":"/ideas/idea-prev-lmic-five-cancer-methylation-test/"},{"id":"idea-prev-therapeutic-hpv-vaccine-cin","kind":"idea","name":"A therapeutic vaccine to clear cervical precancer without surgery","route":"/ideas/idea-prev-therapeutic-hpv-vaccine-cin/"},{"id":"idea-acc-ai-first-pathology-common-cases","kind":"idea","name":"AI-first reading for high-volume common cancer diagnoses, pathologist for the exceptions","route":"/ideas/idea-acc-ai-first-pathology-common-cases/"},{"id":"idea-fund-lmic-radiotherapy-finance","kind":"idea","name":"Blended finance and a low-cost linac to close the global radiotherapy gap","route":"/ideas/idea-fund-lmic-radiotherapy-finance/"},{"id":"idea-bio2-complement-c5ar-blockade","kind":"idea","name":"Block the complement signal that recruits tumour-protecting cells","route":"/ideas/idea-bio2-complement-c5ar-blockade/"},{"id":"idea-fund-lmic-burden-match","kind":"idea","name":"Burden-matched funding for trials led in low- and middle-income countries","route":"/ideas/idea-fund-lmic-burden-match/"},{"id":"idea-acc-community-health-workers-oncology","kind":"idea","name":"Community health workers trained in cancer triage, navigation and home palliative care","route":"/ideas/idea-acc-community-health-workers-oncology/"},{"id":"idea-moon-hpv-vaccine-confidence","kind":"idea","name":"Community-tailored HPV vaccine confidence campaigns with school-based delivery","route":"/ideas/idea-moon-hpv-vaccine-confidence/"},{"id":"idea-tr1-low-dose-immunotherapy-for-lmic","kind":"idea","name":"Confirm ultra-low-dose immunotherapy so it can be afforded where most patients live","route":"/ideas/idea-tr1-low-dose-immunotherapy-for-lmic/"},{"id":"idea-moon-eliminate-infection-cancers","kind":"idea","name":"Eliminate infection-caused cancers: HPV, hepatitis B and C, H. pylori and EBV","route":"/ideas/idea-moon-eliminate-infection-cancers/"},{"id":"idea-hpv-ctdna-cervical","kind":"idea","name":"HPV circulating tumour DNA to guide cervical cancer therapy","route":"/ideas/idea-hpv-ctdna-cervical/"},{"id":"idea-acc-hpv-self-sample-same-day-ablation","kind":"idea","name":"HPV self-testing with same-day treatment as the national cervical programme","route":"/ideas/idea-acc-hpv-self-sample-same-day-ablation/"},{"id":"idea-acc-frugal-hdr-brachytherapy","kind":"idea","name":"Low-cost cobalt-60 brachytherapy for cervical cancer in every regional centre","route":"/ideas/idea-acc-frugal-hdr-brachytherapy/"},{"id":"idea-fund-device-technique-registry","kind":"idea","name":"Mandatory staged registries for new surgical techniques before wide adoption","route":"/ideas/idea-fund-device-technique-registry/"},{"id":"idea-acc-mobile-see-and-treat-units","kind":"idea","name":"Mobile diagnostic units that biopsy, scan and treat on the same visit","route":"/ideas/idea-acc-mobile-see-and-treat-units/"},{"id":"idea-acc-modern-cobalt-bridge","kind":"idea","name":"Modernised cobalt-60 machines as a deliberate bridge where linacs cannot be kept running","route":"/ideas/idea-acc-modern-cobalt-bridge/"},{"id":"idea-acc-nurse-led-chemotherapy-units","kind":"idea","name":"Nurse-led chemotherapy day units with a doctor on a screen","route":"/ideas/idea-acc-nurse-led-chemotherapy-units/"},{"id":"idea-prev-hpv-vaccinate-at-screening","kind":"idea","name":"Offer HPV vaccination to women when they come for cervical screening or treatment","route":"/ideas/idea-prev-hpv-vaccinate-at-screening/"},{"id":"idea-prev-hpv-self-sampling-mailed-default","kind":"idea","name":"Post every woman an HPV self-test kit instead of asking her to book a smear","route":"/ideas/idea-prev-hpv-self-sampling-mailed-default/"},{"id":"idea-moon-radiotherapy-for-everyone-2040","kind":"idea","name":"Radiotherapy for everyone who needs it by 2040","route":"/ideas/idea-moon-radiotherapy-for-everyone-2040/"},{"id":"idea-prev-hpv-same-day-screen-and-treat","kind":"idea","name":"Same-day HPV test and heat treatment of precancer by nurses in low-income settings","route":"/ideas/idea-prev-hpv-same-day-screen-and-treat/"},{"id":"idea-moon-sexual-health-as-toxicity-domain","kind":"idea","name":"Sexual health assessed and treated as a standard toxicity domain","route":"/ideas/idea-moon-sexual-health-as-toxicity-domain/"},{"id":"idea-single-dose-hpv-self-sampling-elimination","kind":"idea","name":"Single-dose HPV vaccination plus HPV self-sampling to reach WHO elimination in low-income countries","route":"/ideas/idea-single-dose-hpv-self-sampling-elimination/"},{"id":"idea-fund-social-impact-bonds-prevention","kind":"idea","name":"Social impact bonds for cancer prevention, repaid from avoided treatment costs","route":"/ideas/idea-fund-social-impact-bonds-prevention/"},{"id":"idea-tr1-include-pregnancy-capable-people-sensibly","kind":"idea","name":"Stop over-excluding people who could become pregnant; study pregnancy exposure","route":"/ideas/idea-tr1-include-pregnancy-capable-people-sensibly/"},{"id":"idea-prev-hpv-single-dose-switch-catchup","kind":"idea","name":"Switch every country to single-dose HPV vaccination and add catch-up to age 26","route":"/ideas/idea-prev-hpv-single-dose-switch-catchup/"},{"id":"idea-reg-metronomic-lmic-phase3-to-label","kind":"idea","name":"Validate low-cost metronomic oral regimens in phase 3 and carry them into guidelines","route":"/ideas/idea-reg-metronomic-lmic-phase3-to-label/"}],"bottleneck":[{"id":"b-misinformation","kind":"bottleneck","name":"Misinformation and unproven therapies","route":"/bottlenecks/b-misinformation/"},{"id":"b-global-access","kind":"bottleneck","name":"Most of the world has almost no cancer care","route":"/bottlenecks/b-global-access/"},{"id":"b-palliative","kind":"bottleneck","name":"Pain relief and palliative care are unavailable to most","route":"/bottlenecks/b-palliative/"},{"id":"b-prevention-adoption","kind":"bottleneck","name":"Prevention we already have is not deployed","route":"/bottlenecks/b-prevention-adoption/"},{"id":"b-surgery-radiation-innovation","kind":"bottleneck","name":"Surgery and radiotherapy cure most, get least","route":"/bottlenecks/b-surgery-radiation-innovation/"}],"pathway":[{"id":"basement-membrane-tissue-barriers","kind":"pathway","name":"Basement membrane & tissue barriers","route":"/pathways/basement-membrane-tissue-barriers/"},{"id":"field-cancerisation","kind":"pathway","name":"Field cancerisation","route":"/pathways/field-cancerisation/"},{"id":"oncogenic-viruses","kind":"pathway","name":"Oncogenic viruses","route":"/pathways/oncogenic-viruses/"}],"paper":[{"id":"paper-mathur-ncrp-cancer-statistics-2020","kind":"paper","name":"Cancer Statistics, 2020: Report from National Cancer Registry Programme, India","route":"/key-papers/paper-mathur-ncrp-cancer-statistics-2020/"},{"id":"paper-patricia-paavonen-lancet-2009","kind":"paper","name":"Efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis","route":"/key-papers/paper-patricia-paavonen-lancet-2009/"},{"id":"paper-hpv-vaccine-england-lancet-2021","kind":"paper","name":"England's HPV programme: cervical cancer down 87% in the first cohort vaccinated at 12-13","route":"/key-papers/paper-hpv-vaccine-england-lancet-2021/"},{"id":"paper-sankaranarayanan-hpv-screening-nejm-2009","kind":"paper","name":"HPV screening for cervical cancer in rural India (Osmanabad)","route":"/key-papers/paper-sankaranarayanan-hpv-screening-nejm-2009/"},{"id":"paper-mujumdar-ivermectin-gynaecological-cancer-2025","kind":"paper","name":"Ivermectin and gynecologic cancer: what's the data?","route":"/key-papers/paper-mujumdar-ivermectin-gynaecological-cancer-2025/"},{"id":"paper-keynote-a18-os-lancet-2024","kind":"paper","name":"KEYNOTE-A18: pembrolizumab with chemoradiotherapy for locally advanced cervical cancer (overall survival)","route":"/key-papers/paper-keynote-a18-os-lancet-2024/"},{"id":"paper-keynote-a18-pfs-lancet-2024","kind":"paper","name":"KEYNOTE-A18: pembrolizumab with chemoradiotherapy for locally advanced cervical cancer (progression-free survival)","route":"/key-papers/paper-keynote-a18-pfs-lancet-2024/"},{"id":"paper-hpv-self-sampling-bmj-2018","kind":"paper","name":"Self-collected HPV samples are as accurate as clinician samples and reach women who never attend screening","route":"/key-papers/paper-hpv-self-sampling-bmj-2018/"},{"id":"paper-siegel-cancer-statistics-2023-cacancer-2023","kind":"paper","name":"Siegel 2023: Cancer statistics, 2023","route":"/key-papers/paper-siegel-cancer-statistics-2023-cacancer-2023/"},{"id":"paper-hpv-vaccine-sweden-nejm-2020","kind":"paper","name":"Swedish registry study: HPV vaccination almost eliminates cervical cancer when given before 17","route":"/key-papers/paper-hpv-vaccine-sweden-nejm-2020/"},{"id":"paper-basu-single-dose-hpv-lancet-oncol-2021","kind":"paper","name":"Vaccine efficacy against persistent HPV 16/18 infection at 10 years after one, two and three doses of quadrivalent HPV vaccine in girls in India","route":"/key-papers/paper-basu-single-dose-hpv-lancet-oncol-2021/"}],"biomarker":[{"id":"pd-l1-cps","kind":"biomarker","name":"PD-L1 CPS (combined positive score)","route":"/biomarkers/pd-l1-cps/"},{"id":"tissue-factor-expression","kind":"biomarker","name":"Tissue factor expression","route":"/biomarkers/tissue-factor-expression/"}],"collection":[{"id":"australia-cancer-screening-programs","kind":"collection","name":"Australia's national cancer screening programs","route":"/collections/australia-cancer-screening-programs/"},{"id":"cdc-nbccedp","kind":"collection","name":"CDC National Breast and Cervical Cancer Early Detection Program","route":"/collections/cdc-nbccedp/"},{"id":"gavi-hpv-programme","kind":"collection","name":"Gavi HPV vaccine support","route":"/collections/gavi-hpv-programme/"},{"id":"ireland-national-screening-service","kind":"collection","name":"Ireland's National Screening Service","route":"/collections/ireland-national-screening-service/"},{"id":"nhs-cancer-screening-programmes","kind":"collection","name":"NHS cancer screening programmes","route":"/collections/nhs-cancer-screening-programmes/"},{"id":"nhs-hpv-vaccination","kind":"collection","name":"NHS HPV vaccination programme","route":"/collections/nhs-hpv-vaccination/"},{"id":"nz-time-to-screen","kind":"collection","name":"Time to Screen (New Zealand national screening)","route":"/collections/nz-time-to-screen/"},{"id":"us-vaccines-for-children","kind":"collection","name":"Vaccines for Children program (US)","route":"/collections/us-vaccines-for-children/"}]}}